Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 1291583 mass balance study in healthy volunteers
NCT05833035Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Apr 2023
- Primary completion
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of verducatib, sponsored by Boehringer Ingelheim. Primary endpoints: Fraction of [14C]-Radioactivity Excreted in Urine Expressed as Percentage of the Administered Dose Over the Time Interval From 0 to the Last Quantifiable Time Point at 336 hours and Fraction of [14C]-Radioactivity Excreted in Faeces Expressed as Percentage of the Administered Dose Over the Time Interval From 0 to the Last Quantifiable Time Point at 336 hours. Started Apr 2023; status: completed.
02
Drugs
verducatib
Beyond the preview
Go deeper on NCT05833035.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05833035.